Across TCGA pan-cancer cohorts, TSPAN19 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TSPAN19 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TSPAN19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TSPAN19 expression acts as an unfavorable survival marker.
LUSC are the cancer types where TSPAN19 Mutation most reproducibly stratifies survival.